Karyopharm Therapeutics Inc. — fact timeline

Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with RA Capital Management valued at gross proceeds of approximately $30 million (effective 2026-03-24).

“On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”) to the Investor in a private placement (collectively, the “Private Placement”).”

Karyopharm Therapeutics Inc. amended Second Amendment to Credit and Guaranty Agreement with Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (effective 2026-02-27).

“On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent”

Karyopharm Therapeutics Inc. incurred credit facility of $12.5 million with term loan lenders at not specified maturing not specified.

“On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025.”

Karyopharm Therapeutics Inc. incurred convertible notes of $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate with holders of convertible notes and other investors at 9.00% maturing 2028 and 2029.

“On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due 2029.”

Kristin Abate was appointed as Vice President, Chief Accounting Officer at Karyopharm Therapeutics Inc..

“On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.”

Michael Mason resigned as Executive Vice President, Chief Financial Officer and Treasurer at Karyopharm Therapeutics Inc..

“On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.”

Karyopharm Therapeutics Inc. incurred convertible notes of approximately $111.0 million aggregate principal amount of the Company’s new secured convertible senior notes.

“approximately $111.0 million aggregate principal amount of the Company’s new secured convertible senior notes”

Karyopharm Therapeutics Inc. incurred term loan of $100.0 million with Wilmington Savings Fund Society, FSB, as the administrative agent and collateral agent for the Lenders at Term SOFR (subject to a floor of 3.00%) plus 9.25% per annum maturing May 8, 2028.

“The Credit Agreement provides for a senior secured term loan facility of $100.0 million (the “Term Loan”).”

Karyopharm Therapeutics Inc. entered into Exchange Agreements with a limited number of existing holders of 2025 Notes who are institutional accredited investors and qualified institutional buyers valued at approximately $148.0 million aggregate principal amount (effective 2024-05-08).

“On the Closing Date, the Company also entered into privately-negotiated agreements (the “Exchange Agreements”) with a limited number of existing holders of 2025 Notes who are both institutional “accredited investors” (within the meaning of Rule 501(a)(1), (2), (3) or (7) promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) and “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) (such existing holders, the “Exchange Participants”) to exchange approximately $148.0 million aggregate principal amount of the Exchange Participants’ existing 2025”

Karyopharm Therapeutics Inc. entered into Credit Agreement with the lenders party thereto, and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent valued at $100.0 million (effective 2024-05-08).

“On May 8, 2024 (the “Closing Date”), the Company entered into a credit and guaranty agreement (the “Credit Agreement”) with the guarantors party thereto, the lenders party thereto (the “Lenders”), and Wilmington Savings Fund Society, FSB, as the administrative agent and collateral agent for the Lenders (in such capacity, the “Term Loan Agent”). The Credit Agreement provides for a senior secured term loan facility of $100.0 million (the “Term Loan”).”

Karyopharm Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $33.1 million. Guidance reaffirmed.

“Readouts and Potential Approvals from the Company’s Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO”